VolitionRX (NYSEAMERICAN:VNRX) Stock Price Crosses Below 50-Day Moving Average – Here’s Why

Posted by Francis Steltz on Jul 26th, 2026

VolitionRX Limited (NYSEAMERICAN:VNRX – Get Free Report) crossed below its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $1.68 and traded as low as $0.99. VolitionRX shares last traded at $1.00, with a volume of 176,127 shares trading hands.

Analysts Set New Price Targets

VNRX has been the topic of several research analyst reports. D. Boral Capital reissued a “hold” rating on shares of VolitionRX in a research report on Monday, April 20th. Maxim Group reaffirmed a “buy” rating and set a $4.00 price target on shares of VolitionRX in a research note on Thursday, June 18th. HC Wainwright decreased their price target on shares of VolitionRX from $30.00 to $20.00 and set a “buy” rating on the stock in a report on Thursday, April 2nd. Benchmark restated a “hold” rating on shares of VolitionRX in a report on Tuesday, June 2nd. Finally, Citigroup cut VolitionRX to a “hold” rating in a report on Monday, April 20th. Two analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $28.00.

Get Our Latest Research Report on VolitionRX

VolitionRX Price Performance

The business’s 50-day simple moving average is $1.68 and its two-hundred day simple moving average is $3.30. The stock has a market capitalization of $8.63 million, a price-to-earnings ratio of -0.24 and a beta of 1.12.

VolitionRX (NYSEAMERICAN:VNRX – Get Free Report) last released its quarterly earnings data on Thursday, May 14th. The medical research company reported ($0.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.27). The firm had revenue of $0.99 million for the quarter, compared to the consensus estimate of $1.52 million. As a group, sell-side analysts expect that VolitionRX Limited will post -2.4 EPS for the current year.

Institutional Investors Weigh In On VolitionRX

A number of large investors have recently modified their holdings of VNRX. Geode Capital Management LLC boosted its holdings in VolitionRX by 9.8% in the 4th quarter. Geode Capital Management LLC now owns 963,986 shares of the medical research company’s stock worth $246,000 after acquiring an additional 85,816 shares during the period. Armistice Capital LLC boosted its stake in shares of VolitionRX by 10.4% in the third quarter. Armistice Capital LLC now owns 9,380,425 shares of the medical research company’s stock valued at $6,367,000 after purchasing an additional 887,351 shares during the period. Squarepoint Ops LLC purchased a new stake in VolitionRX during the 4th quarter worth $34,000. Jane Street Group LLC acquired a new position in VolitionRX in the 4th quarter worth $28,000. Finally, Citadel Advisors LLC lifted its holdings in VolitionRX by 70.1% in the 3rd quarter. Citadel Advisors LLC now owns 329,520 shares of the medical research company’s stock worth $224,000 after buying an additional 135,775 shares in the last quarter. Institutional investors and hedge funds own 8.09% of the company’s stock.

VolitionRX Company Profile

(Get Free Report)

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.